JPWO2023194339A5 - - Google Patents

Info

Publication number
JPWO2023194339A5
JPWO2023194339A5 JP2024559386A JP2024559386A JPWO2023194339A5 JP WO2023194339 A5 JPWO2023194339 A5 JP WO2023194339A5 JP 2024559386 A JP2024559386 A JP 2024559386A JP 2024559386 A JP2024559386 A JP 2024559386A JP WO2023194339 A5 JPWO2023194339 A5 JP WO2023194339A5
Authority
JP
Japan
Prior art keywords
diffraction pattern
ray
crystal morphology
measured
ranifibranol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511847A (ja
JP2025511847A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/058743 external-priority patent/WO2023194339A1/en
Publication of JP2025511847A publication Critical patent/JP2025511847A/ja
Publication of JP2025511847A5 publication Critical patent/JP2025511847A5/ja
Publication of JPWO2023194339A5 publication Critical patent/JPWO2023194339A5/ja
Pending legal-status Critical Current

Links

JP2024559386A 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態 Pending JP2025511847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305456 2022-04-05
EP22305456.0 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (3)

Publication Number Publication Date
JP2025511847A JP2025511847A (ja) 2025-04-16
JP2025511847A5 JP2025511847A5 (https=) 2026-04-08
JPWO2023194339A5 true JPWO2023194339A5 (https=) 2026-04-08

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559386A Pending JP2025511847A (ja) 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態

Country Status (14)

Country Link
US (1) US20250243192A1 (https=)
EP (1) EP4504725A1 (https=)
JP (1) JP2025511847A (https=)
KR (1) KR20250002337A (https=)
CN (1) CN119301120A (https=)
AR (1) AR128985A1 (https=)
AU (1) AU2023250118A1 (https=)
CA (1) CA3247273A1 (https=)
IL (1) IL316075A (https=)
MX (1) MX2024012348A (https=)
PY (1) PY2324870A (https=)
TW (1) TW202404966A (https=)
UY (1) UY40216A (https=)
WO (1) WO2023194339A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240047402A (ko) * 2021-08-12 2024-04-12 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도
CN120857930A (zh) 2023-01-19 2025-10-28 伊文蒂瓦公司 拉尼兰诺制剂
KR20260020956A (ko) 2023-06-05 2026-02-12 엥방티바 간 질환을 가진 환자의 내장 혈관 확장증의 치료에 사용하기 위한 라니피브라노르
WO2025061927A1 (en) * 2023-09-22 2025-03-27 Inventiva Method of making lanifibranor
WO2025132989A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025132955A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
TW202543596A (zh) 2024-03-15 2025-11-16 法商因文帝華公司 預防接受過氧化物酶體增生劑活化受體(ppar)促效劑治療患者之血液病症
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025238200A1 (en) 2024-05-17 2025-11-20 Inventiva Treatment of a liver disease in patients with hepatic impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
WO2022261410A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
KR20240047402A (ko) 2021-08-12 2024-04-12 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 라니피브라노르의 결정형, 이의 제조 방법 및 이의 용도

Similar Documents

Publication Publication Date Title
JP5714824B2 (ja) 1−4−(5−シアノインドール−3−イル)ブチル−4−(2−カルバモイルベンゾフラン−5−イル)ピペラジン塩酸塩の多形相
JP2025176008A5 (https=)
ES2351958T3 (es) 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis.
JP2009537603A (ja) 5−アミノ−3−(2’,3’−ジ−O−アセチル−ベータ−D−リボフラノシル)−3H−チアゾロ[4,5−d]ピリミジン−2−オンのマレイン酸塩のA型及びB型結晶形
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
JPWO2023194339A5 (https=)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2024095561A5 (https=)
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
CN110862389A (zh) 一种阿哌沙班晶型的制备方法
EA020545B1 (ru) Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
CN111592485A (zh) 盐酸替罗非班及其游离碱的晶型及其制备方法
US6673935B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2010131035A1 (en) Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2008092327A1 (fr) Cristaux demi-hydratés de voglibose, leur procédé de préparation, et préparation pharmaceutique les contenant
WO2013013595A1 (zh) 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法
CN111278828A (zh) 巴瑞替尼磷酸盐的新晶型及其制备方法
JPWO2024104354A5 (https=)
CN105017120B (zh) 依折麦布与烟酰胺药物共晶及其制备方法
JP2012503641A (ja) アカンプロセートカルシウムの多形体
WO2025176138A1 (zh) 亮氨酸二肽的盐
JPWO2021204762A5 (https=)
JPS59104358A (ja) 1α,24−ジヒドロキシコレカルシフエロ−ルの一水塩及びその製造法
TW460471B (en) Alternate crystal form of tazofelone
CN111303226A (zh) 利用索非布韦晶型i制备索非布韦晶型vi的方法